吡柔比星与卡介苗交替灌注预防浅表性膀胱癌术后复发的.pdf

∃988∃临床军医杂志(ClinJMedOffic)2009年12月第37卷第6期

吡柔比星与卡介苗交替灌注预防浅表性膀胱癌术后复发的疗效观察

宋光庆1,罗俊卿1,宋小军2(1武警湖南总队医院;2武警湖南总队卫生处,湖南长沙410006)

摘要:目的观察吡柔比星(THP)与卡介苗(BCG)交替灌注的化学免疫疗法预防浅表性膀胱癌术后复发的疗效。方法将128例行经尿
道膀胱癌电切术的浅表性膀胱癌患者,随机分为3组:组行THP与BCG交替灌注(48例)、组行THP灌注(40例)、!组行BCG灌注
(40例),随访5年,比较三组肿瘤复发率。结果随访18月~5年,平均4.2年,三组患者复发率分别为8.3%(4/48)、17.5%(7/40)和
20%(8/40),、!组比较差异无统计学意义(P>0.05),组复发率低于、!组(P<0.05)。结论吡柔比星与卡介苗交替灌注的化
学免疫疗法明显降低了浅表性膀胱癌的术后复发率,优于单用化疗药物或免疫制剂。
关键词:浅表性膀胱癌;吡柔比星;卡介苗;膀胱灌注
中图分类号:R73714文献标志码:A文章编号:16713826(2009)06098802

CurativeEffectObservationofPreventingBladderCarcinomaRecidivationafterOperati
onbyPerfusingPirarubicinandBacilleCalmetteGuerininTurn

SongGuangqing1,LuoJunqing1,SongXiaojun2(1.HunanProvincialCorpsHospita,lChinesePeople∀sArmedPolice
Forces;2.DepartmentofEpidemiology,HunanProvincialCorps,ChinesePeople∀sArmedPoliceForces,Changsha410006,
China)

Abstract:ObjectiveToobservetheeffectofpreventingbladdercarcinomarecidivationaftersurgicaloperationbyperfusingpira
rubicinandbacillecalmetteguerininturn.MethodsAtotalof128patientswithbladdercarcinomaafterTURBtweredividedin
tothreegroupsatrandom,.ie.GroupA(perfusingpirarubicinandbacillecalmetteguerininturn),GroupB(perfusingpirarubi
cin)andGroupC(perfusingbacillecalmetteguerin).Theirrelapseratesinfiveyearswerecompared.ResultsAfter18months
to5years∀followupvisit(4.2yearsinaverage),itwasfoundedthattherelapserateswere8.3%(4/48),17.5%(7/40)and
20%(8/40)respectivelyinGroupA,GroupBandGroupC.TherelapserateofGroupAwaslowerthanthatofGroupBorGroup
C(P<0.05).ConclusionThechemoimmunotherapyofpreventingbladdercarcinomarecidivationbyperfusingpirarubicinand
bacillecalmetteguerininturnisbetterthanchemotherapeuticsorimmunotherapyalone.
Keywords:bladderneoplasm;pirarubicin;bacillecalmetteguerin;bladderirrigation

膀胱癌在泌尿系肿瘤中发病率排第一位,对于浅表性例,多发肿瘤48例。术后均经病检证实为膀胱移行细胞
膀胱癌,目前最常用的治疗方法为经尿道膀胱癌电切术癌,术后均定期作膀胱灌注。
(transurethralresectionofbladdertumor,TURBt),但术后复1.2灌注方法128例患者随机分为3组,组(48例)
发率高,因此,探索一种合理有效的膀胱灌注药物对预防采用THP与BCG交替